Fenretinide in Treating Patients With Cervical Neoplasia

Completed · Phase 3 · Has a placebo group

Conditions studied: Cervical Cancer, Precancerous Condition

In brief

RATIONALE: Chemoprevention uses drugs to try and prevent development of cancer. Fenretinide may be effective in treating cervical neoplasia and preventing cervical cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of fenretinide to placebo in treating patients with cervical neoplasia.

Key facts

Study ID

NCT00003075

Run by

M.D. Anderson Cancer Center

People needed

39

Starts

1993-03-05

Expected to finish

2001-05-01

Last updated by the study team

2018-10-24

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.